A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study

Targeted next-generation sequencing (tNGS) and ex vivo drug sensitivity/resistance profiling (DSRP) have laid foundations defining the functional genomic landscape of acute myeloid leukemia (AML) and premises of personalized medicine to guide treatment options for patients with aggressive and/or che...

Descripción completa

Detalles Bibliográficos
Autores principales: Collignon, A., Hospital, M. A., Montersino, C., Courtier, F., Charbonnier, A., Saillard, C., D’Incan, E., Mohty, B., Guille, A., Adelaïde, J., Carbuccia, N., Garnier, S., Mozziconacci, M. J., Zemmour, C., Pakradouni, J., Restouin, A., Castellano, R., Chaffanet, M., Birnbaum, D., Collette, Y., Vey, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266815/
https://www.ncbi.nlm.nih.gov/pubmed/32488055
http://dx.doi.org/10.1038/s41408-020-0330-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266815/
https://www.ncbi.nlm.nih.gov/pubmed/32488055
http://dx.doi.org/10.1038/s41408-020-0330-5

Ejemplares similares